An interventional study of Transcatheter Aortic Valve Replacement in Aortic Valve Stenosis, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 11th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2025, is one of 37 with no phase, reaches primary completion later than 26 of the 50 other live ones, and was the 55th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 232 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 490 across the 22 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized controlled clinical study designed to evaluate the real-world performance of the VitaFlow Liberty® Flex Transcatheter Aortic Valve Retrievable and Steerable Delivery System (Investigational Device) for treating severe aortic stenosis (AS) in challenging anatomies. The study will compare it against the VitaFlow Liberty® Retrievable Delivery System (Control Device), which lacks steerability.
Key Study Elements:
Objective: The primary objective is to assess the device's performance using the incidence of a composite endpoint before hospital discharge. This endpoint includes permanent pacemaker implantation (PPI), valve-in-valve (ViV) implantation, or moderate-to-severe paravalvular leakage (PVL).
Design: A prospective, multicenter RCT with 1:1 randomization (Experimental: VitaFlow Liberty® Flex vs. Control: VitaFlow Liberty®). Approximately 15 sites in China will participate. Subjects undergo follow-up at discharge, 30 days, and 1 year post-procedure. An independent data center handles management and analysis.
Population: Patients with severe AS (echo confirmed: peak velocity ≥4.0 m/s, mean gradient ≥40 mmHg, or AVA ≤1.0 cm²/AVAi ≤0.6 cm²/m²) AND preoperative CTA showing a challenging aortic-left ventricular angle >60°. NYHA class ≥II is required.
Devices:
Investigational: VitaFlow Liberty® Flex (Retrievable \& Steerable Delivery System - Models DSRS21/24/27/30/A series; Loading Tools LT-S series).
Control: VitaFlow Liberty® (Retrievable Delivery System - Models DSR21/24/27/30; Loading Tools LT series).
Endpoints:
Primary: Composite of PPI, ViV, or moderate-to-severe PVL before discharge.
Secondary: Include individual components of the primary endpoint (ViV, PVL) immediately post-procedure, procedural success (VARC-3), technical assistance rates, valve retrievals, implantation depth, arch/valve crossing performance, valve hemodynamics (gradient, area, leak, LVEF), NYHA class, Major Adverse Cardiac and Cerebrovascular Events (MACCE - all-cause death, MI, stroke, reoperation), major vascular complications (at discharge/30 days).
Key Inclusion: Severe AS, challenging anatomy (aortic-LV angle >60°), NYHA ≥II, informed consent.
Key Exclusions: Device/contrast allergies, anticoagulant intolerance, active infection, severe vascular disease prohibiting access, ascending aorta ≥55mm, unsuitable aortic root anatomy, intracardiac mass/thrombus, recent MI (\<30 days), severe concomitant mitral/tricuspid regurgitation, cardiogenic shock, severe LV dysfunction (LVEF\<20%), hematologic abnormalities, pregnancy/breastfeeding, participation in other device trials.
Visits: Screening (≤30d pre-op), Procedure (intra-op to 24h post-op), Discharge (≤7d post-op), 30d Follow-up (±7d), 12m Telephone FU (±1m).
Sample Size: Planned enrollment of 232 subjects (116 per group), calculated for superiority testing. Based on an expected composite endpoint rate of 21% for the Flex system vs. a historical rate of 38% for non-steerable systems (Superiority margin Δ1=0%, one-sided α=2.5%, Power=80%, accounting for 5% dropout).
Purpose: This study aims to demonstrate the superiority of the retrievable and steerable VitaFlow Liberty® Flex delivery system in reducing the composite rate of key adverse events (PPI, ViV, significant PVL) at discharge compared to the non-steerable system, specifically in patients with severe AS and anatomically challenging aortic-left ventricular angles.
A Prospective, Multicenter, Randomized Controlled Clinical Trial Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Retrievable and Steerable Delivery System for Severe Aortic Stenosis in Challenging Anatomies
Type: Prospective, multicenter, open-label, 1:1 randomized controlled superiority trial
Randomization: Centralized electronic system
Blinding: Unblinded (procedural nature precludes blinding)
Study Arms:
Experimental: VitaFlow Liberty® Flex TAVR System (Retrievable \& Steerable)
Control: VitaFlow Liberty® TAVR System (Retrievable, Non-Steerable)
Follow-up Schedule:
Pre-discharge (≤7 days post-op)
30 days (±7 days)
12 months (±1 month, telephone)
Oversight: Independent Clinical Events Committee (CEC), Data Monitoring Committee (DMC), and Core Laboratories for imaging/ECG analysis
Centers: \~15 experienced TAVR centers across China
3. Investigational and Control Devices
Device Component:VitaFlow Liberty® FLEX (Investigational) VitaFlow Liberty® (Control) Delivery System Type:Retrievable \& Steerable(Investigational) Retrievable (Non-Steerable)(Control)
4. Study Population
Diagnosis: Severe symptomatic AS confirmed by echocardiography:
Peak aortic velocity ≥4.0 m/s OR Mean gradient ≥40 mmHg OR Aortic valve area (AVA) ≤1.0 cm² (or AVAi ≤0.6 cm²/m²) Anatomical Inclusion: Pre-op CT angiography (CTA) with 3D reconstruction demonstrating aortic-LV angle >60° (validating challenging anatomy).
Symptoms: NYHA Functional Class ≥II.
Key Exclusion Criteria:
Allergy to device materials (nitinol), contrast, or antiplatelets/anticoagulants Active infection/endocarditis Severe vascular disease prohibiting access Ascending aorta diameter ≥55mm Unsuitable aortic root anatomy (e.g., heavy calcification affecting expansion) Intracardiac thrombus/mass Recent MI (\<30 days) Severe mitral/tricuspid regurgitation LVEF \<20% Hematologic disorders (leukopenia, thrombocytopenia, coagulopathy) Pregnancy or concurrent device trials
5. Endpoints
Primary Endpoint:
Composite of PPI, ViV implantation, or moderate-to-severe PVL before discharge.
Secondary Endpoints:
Procedural:
ViV rate (immediate post-op) Moderate-to-severe PVL (immediate post-op) Technical assistance crossing rate Valve retrieval attempts Valve implantation depth Arch/valve crossing performance Procedural success (VARC-3 criteria*)
Clinical:
PPI rate (discharge, 30 days) MACCE** (discharge, 30 days): All-cause death, MI, stroke, reoperation Major vascular complications
Hemodynamic/Echocardiographic:
Valve orifice area, mean gradient, peak velocity Degree of stenosis/regurgitation LVEF (immediate, discharge, 30 days)
Functional: NYHA Class improvement (discharge, 30 days)
*VARC-3: Valve Academic Research Consortium-3 criteria for technical success.
**MACCE: Major Adverse Cardiac and Cerebrovascular Events.
6. Statistical Analysis \& Sample Size Hypothesis: Superiority of VitaFlow Liberty® Flex
Assumptions:
Historical composite endpoint rate (non-steerable systems): 38% Expected composite rate (steerable system): 21% Superiority margin (Δ1): 0% Power: 80% \| One-sided α: 2.5% \| Dropout: 5% Sample Size: 232 subjects (116 per arm)
Analysis:
Primary endpoint: Chi-square/Fisher's exact test Secondary endpoints: Mixed-effects models accounting for site variability Subgroup analyses: Valve size, center volume, baseline aortic-LV angle
7. Study Procedures
Screening (≤30 days pre-op): Echocardiography, CTA, NYHA assessment, informed consent.
Procedure: TAVR under standard anesthesia. Randomization pre-insertion. Discharge (≤7 days): Echo, ECG, NYHA, MACCE/vascular complication assessment. 30-Day Visit: Clinical exam, echo, ECG, lab tests, NYHA, MACCE. 12-Month Follow-up: Telephone assessment for mortality/MACCE.
8. Ethical \& Regulatory Considerations
Approved by institutional review boards (IRBs) at all sites. Conducted per ICH-GCP, Declaration of Helsinki, and Chinese regulatory requirements.
Independent DMC reviews safety data quarterly.
9. Significance and Innovation
This trial addresses a critical unmet need in TAVR: improving outcomes in patients with challenging aortic anatomies. If superiority is demonstrated, the steerable delivery system may become the preferred option for:
Reducing PPI rates (linked to anatomical precision) Mitigating PVL (via optimal deployment) Avoiding ViV (through recapture/repositioning) Enhancing first-attempt success in tortuous anatomies
Conclusion:
This rigorously designed RCT will provide Level A evidence on the clinical utility of steerable TAVR technology in high-risk anatomies, potentially establishing a new standard for managing complex AS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter Aortic Valve Retrievable and Controllable Flex Delivery System (VitaFlow Liberty® Flex)
Device: Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve and Delivery System (Self-Expanding Valve, Non-Controllable Flex Delivery System)
Device: Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.
the number of occurrences/total number of occurrences
Incidence of composite endpoint events before discharge (permanent pacemaker implantation, valve-in-valve, or moderate-to-severe paravalvular leak) calculated as number of occurrences/total number of occurrences
Time frame: Perioperative/Periprocedural"
Incidence of valve-in-valve
Incidence of valve-in-valve calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural
Incidence of Moderate-to-severe paravalvular leak
Incidence of Moderate-to-severe paravalvular leak calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural
Incidence of Other technical assistance crossing rate
Incidence of Other technical assistance crossing rate (immediately post-procedure) calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural
Incidence of valve retrievals
Incidence of valve retrievals calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural
Valve implantation depth calculated as Intraoperative images
Valve implantation depth calculated as Intraoperative images
Time frame: Perioperative/Periprocedural
Incidence of Permanent Pacemaker Implantation
Incidence of Permanent Pacemaker Implantation calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural, 30 days,
Arch Crossing and Valve Crossing Performance calculated as assessment scale
Arch Crossing and Valve Crossing Performance calculated as assessment scale
Time frame: Perioperative/Periprocedural
Number of participants with Valve Performance Evaluation
Valve Performance Evaluation, Including: Valve Orifice Area, Mean Transvalvular Pressure Gradient, Peak Transvalvular Velocity, Degree of Valve Stenosis, Degree of Valve Regurgitation, Degree of Paravalvular Leak, Left Ventricular Ejection Fraction (LVEF) calculated as cardiac uhrasonography
Time frame: Perioperative/Periprocedural, 30 days,
NYHA Functional Class Assessment NYHA classification
NYHA Functional Class Assessment NYHA classification: Divided into four levels, Grade I: No discomfort in daily activities, and no restriction in physical activities. Grade II: Mild activity restriction, no symptoms at rest, but daily activities (such as climbing stairs) can cause fatigue and palpitation. Grade III: obvious activity limitation, no symptoms at rest, but slight activity (such as walking) will cause symptoms. Grade Ⅳ: There are symptoms at rest, and any activity aggravates discomfort.
Time frame: Perioperative/Periprocedural, 30 days
Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCE),MACCE Includes: All-Cause Mortality, Myocardial Infarction, All Stroke, Reoperation Due to Valve Dysfunction calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural, 30 days,
Incidence of Major Vascular Complications
Incidence of Major Vascular Complications calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural, 30 days
Procedural Success Rate (VARC-3 Definition)
Procedural Success Rate (VARC-3 Definition) calculated as: Occurred/Total
Time frame: Perioperative/Periprocedural
Started Jul 2025 (actual). Primary completion is estimated for Aug 2026, 13 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 13 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.